Clinical trials: Hypoglycemia
Diabetes Mellitus, Type 1, Hypoglycemia
A Study to Investigate Safety and Effectiveness of Porcine Pancreatic Cells (OPF-310) in Patients With Type 1 Diabetes Mellitus
This study is First In Human study for Encapsulated Porcine Islet Cells for Xenotransplantation (OPF-310). The purpose of this study to assess the safety, tolerability, and efficacy of OPF-310 transplantation and to define the…
- Conditions
- Diabetes Mellitus, Type 1, Hypoglycemia, Islet Cell Transplantation, Type 1 Diabetes
- Trial name
- NCT06575426
- Testing
- OPF-310
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Otsuka Pharmaceutical Factory, Inc.
Healthy
Evaluation of Hypo-Safe Hypoglycaemia Alarm Device - the Pilot 2 Study - Healthy Subjects
The objective of this pilot trial is to demonstrate the safety and the performance of the Hyposafe hypoglycaemia alarm device before conducting clinical trials in type 1 diabetes patients.
- Trial name
- NCT02402153
- Testing
- Hyposafe device
- Where
- Denmark
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- UNEEG Medical A/S
Diabetes Mellitus, Type 2, Hypoglycemia
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to learn more about how tirzepatide affects the body's response to low blood sugar (hypoglycemia). The study is open to participants with type 2 diabetes.
- Trial name
- NCT04050553
- Testing
- Tirzepatide
- Where
- Austria
- Volunteers
- 42 people
- Sponsor
- Eli Lilly and Company
Hypoglycemia, Glucose Metabolism Disorders
Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults
The objective of the trial is to assess the effect of single subcutaneous doses of dasiglucagon versus placebo on post-prandial plasma glucose nadir following a Mixed Meal Test in Roux-en-Y Gastric Bypass (RYGB) subjects
- Trial name
- NCT04824872
- Testing
- Dasiglucagon
- Sponsor
- Zealand Pharma
Postprandial Hypoglycemia
Glucose Response to a Formula for Patients at Risk of Hypoglycaemia
This study assesses the glycemic responses to several nutritional products.
- Trial name
- EFFECT (NCT05676385)
- Testing
- First concept product (containing 50 grams of carbohydrates), Second concept product (containing 50 grams of carbohydrates), Reference product (containing 50 grams of carbohydrates)
- Where
- Netherlands
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Nutricia Research
Diabetes Mellitus
A Two Part Study of Peroral Insulin in Type 2 Diabetes
Insulin is normally not bioavailable when taken through the oral route, as degradation of the molecule may occur both in the ventricle and in the intestine.
- Trial name
- ORA2 (NCT00990444)
- Testing
- Insulin in Dextran Matrix
- Where
- Sweden
- Volunteers
- 32 people
- Sponsor
- Bows Pharmaceuticals AG
Congenital Hyperinsulinism
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of HM15136 when used as add-on therapy in subjects with CHI with persistent hypoglycemia while on standard of care treatment (SoC).
- Trial name
- NCT04732416
- Testing
- HM15136
- Where
- 7 sites in United States, Germany and 3 more
- Volunteers
- 17 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes Mellitus, Type 1
A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus
The main purpose of this study is to evaluate the response of glucagon to insulin-induced low blood sugar after administration of the study drug LY3532226 in participants with type 1 diabetes mellitus (T1DM).
- Trial name
- NCT05887999
- Testing
- LY3532226
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Postbariatric Hypoglycemia
Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia
This clinical study will evaluate whether taking an investigational drug called exendin 9-39 is safe, well-tolerated, and helps to prevent low blood sugar in people who have had bariatric surgery and later develop a rare…
- Trial name
- PREVENT (NCT03373435)
- Testing
- exendin 9-39
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Eiger BioPharmaceuticals